Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 1:06 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2545–2568 of 184,974 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: NOT program Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Zirconia-based Primary Anterior Crowns With Retention Grooves Versus Without Retention Grooves

NCT06354647
View directory record Official record
Conditions
Dental Caries, Tooth Decay
Interventions
Zirconia-based primary anterior crowns with retention grooves, Zirconia-based primary anterior crowns without retention grooves
Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
2 Years to 6 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Nov 3, 2026, 1:06 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Ciprofloxacin XR Drug Interaction Study With MMX® Mesalazine/Mesalamine

NCT01402947
View directory record Official record
Conditions
Healthy
Interventions
Ciprofloxacin XR + MMX Placebo, MMX Mesalazine/mesalamine + Ciprofloxacin XR
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Nov 3, 2026, 1:06 AM EST
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Enhancing Cognitive Control Abilities Using Mobile Technology in a Senior Living Community

NCT04905849
View directory record Official record
Conditions
Aging, Cognitive Change
Interventions
Adaptive Cognitive Control Trainer (ACCT), Active Control App
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Nov 3, 2026, 1:06 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

A Randomized Trial of Behavioral Economic Approaches to Reduce Unnecessary Opioid Prescribing

NCT03825549
View directory record Official record
Conditions
Acute Pain
Interventions
Individual audit feedback, Peer comparison feedback
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Nov 3, 2026, 1:06 AM EST
Completed No phase listed Observational

The Effect of Implementing Hyper-acute Stroke Guidelines on Decision-Making for or Against Thrombolytic Therapy for Stroke in the Emergency Department

NCT01050049
View directory record Official record
Conditions
Stroke
Interventions
Not listed
Lead sponsor
Temple University
Other
Eligibility
19 Years and older
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2010 · Synced Nov 3, 2026, 1:06 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Metformin During Nicotine Withdrawal

NCT03593538
View directory record Official record
Conditions
Smoking, HIV-1-infection
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Nov 3, 2026, 1:06 AM EST
Completed Phase 2 Interventional Results available

Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC

NCT02716038
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
MPDL3280A, Carboplatin, Nab-paclitaxel
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Nov 3, 2026, 1:06 AM EST
Active, not recruiting Not applicable Interventional

Post Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System

NCT03626038
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Post-Traumatic Arthritis, Psoriatic Arthritis, Proximal Humeral Fracture
Interventions
A.L.P.S. Proximal Humerus Plating System
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Nov 3, 2026, 1:06 AM EST
Completed Phase 2 Interventional Results available

A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).

NCT04425538
View directory record Official record
Conditions
COVID-19
Interventions
Infliximab
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Nov 3, 2026, 1:06 AM EST
Completed No phase listed Observational Results available

IMAS Optimization and Applicability in Acute and Subacute Stroke.

NCT05469438
View directory record Official record
Conditions
Acute Stroke
Interventions
Not listed
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Nov 3, 2026, 1:06 AM EST
Active, not recruiting Not applicable Interventional

Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device

NCT06192758
View directory record Official record
Conditions
Prostate, Cancer
Interventions
TheraSphere PCa
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
50 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 3, 2026, 1:06 AM EST
Completed Phase 1 Interventional

A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).

NCT01021358
View directory record Official record
Conditions
Lymphoma, Chronic Lymphocytic Leukemia, Solid Tumors
Interventions
ABT-263, Ketoconazole
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 20, 2010 · Synced Nov 3, 2026, 1:06 AM EST
Active, not recruiting Phase 1 Interventional

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

NCT04454658
View directory record Official record
Conditions
Myelofibrosis (MF)
Interventions
ABBV-744, Navitoclax, Ruxolitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
10
States / cities
Sacramento, California • Lebanon, New Hampshire • Buffalo, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Nov 3, 2026, 1:06 AM EST
Completed Phase 2 Interventional Results available

Extending Ketamine's Effects in OCD With Exposure and Response Prevention (EX/RP)

NCT02062658
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Ketamine, Exposure and Response Prevention
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Nov 3, 2026, 1:06 AM EST
Completed No phase listed Observational

Study to Measure the Prevalence of Asynchrony In Mechanically Ventilated Patients

NCT01049958
View directory record Official record
Conditions
Patient/Ventilator Asynchrony
Interventions
Not listed
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Nov 3, 2026, 1:06 AM EST
Completed Phase 2Phase 3 Interventional Results available

The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

NCT04674358
View directory record Official record
Conditions
Dry Eye, Dry Eye Syndromes
Interventions
Reproxalap Ophthalmic Solution (0.25%), Vehicle Opthalmic Solution
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Nov 3, 2026, 1:06 AM EST
Withdrawn Not applicable Interventional

Comprehensive Informatics Framework for Comparative Effectiveness Research (CER) Dissemination

NCT01493258
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
iCOPE Intervention group
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
3
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Nov 3, 2026, 1:06 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Spinal Stability

NCT01060358
View directory record Official record
Conditions
Spine Stability, Low Back Pain
Interventions
method (non-surgical) to measure neuromuscular neutral zones
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Nov 3, 2026, 1:06 AM EST
Completed Phase 2 Interventional Results available

A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder

NCT06340958
View directory record Official record
Conditions
Adjunctive Treatment of Major Depressive Disorder (MDD)
Interventions
CLE-100, Placebo
Drug
Lead sponsor
Clexio Biosciences Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
23
States / cities
La Jolla, California • Lafayette, California • Upland, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Nov 3, 2026, 1:06 AM EST
Completed No phase listed Observational Results available

BlueSync Field Evaluation

NCT03518658
View directory record Official record
Conditions
Bradycardia
Interventions
Evaluation Group, Control Group (Historical)
Other
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
11
States / cities
Palo Alto, California • Hartford, Connecticut • Daytona Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Nov 3, 2026, 1:06 AM EST
Recruiting Phase 2Phase 3 Interventional

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

NCT07001748
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis
Interventions
Standard of Care Chemotherapy, Biospecimen Collection, Computed Tomography, Diagnostic Laparoscopy, Intraperitoneal Port Placement, Magnetic Resonance Imaging, Intraperitoneal Paclitaxel
Drug · Procedure
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
78
States / cities
Irvine, California • Los Angeles, California • Orange, California + 64 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 3, 2026, 1:06 AM EST
Terminated Phase 2 Interventional Results available

Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149

NCT03997448
View directory record Official record
Conditions
Gastroesophageal Cancer, Adenocarcinoma
Interventions
Pembrolizumab, Abemaciclib
Drug
Lead sponsor
Nataliya Uboha
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Indianapolis, Indiana • Iowa City, Iowa • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Nov 3, 2026, 1:06 AM EST
Withdrawn Not applicable Interventional

Lung Irradiation for COVID-19 Pneumonia

NCT04393948
View directory record Official record
Conditions
SARS-CoV 2
Interventions
Phase 1, Phase 2
Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Nov 3, 2026, 1:06 AM EST
Completed Phase 1 Interventional

A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351

NCT03555955
View directory record Official record
Conditions
Hematologic Malignancy, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes
Interventions
CPX-351
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
11
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Westwood, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Nov 3, 2026, 1:06 AM EST